All In Biotech

Drug Trial Radar · NCT05693558

NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia

A Proof-of-concept Study With NVD-003, an Autologous Osteogenic Bone Graft, in the Treatment of Congenital Pseudarthrosis of the Tibia in Pediatric Patients.

Last checked: Nov 19, 2026Latest source record: Jan 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

4

Planned (sponsor's estimate)

Start

Nov 24, 2022

Primary completion

Jan 2025

Study completion Jan 2026

Sponsor

Lead sponsor
Novadip BiosciencesIndustry
Sponsor type
Industry
First posted
Jan 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single arm, multi-country, multi-center study in pediatric patients, suffering from congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.

Conditions

  • Congenital Pseudarthrosis of Tibia

Interventions

  • NVD-003, an autologous 3D scaffold free osteogenic graftBiological

    Bone correction and grafting surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary objective: safety short (≤3 months) and mid long-term (>3-12 months): : Descriptive analysisTime frame: Up to 12 months post-grafting surgery

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Adult/Pediatric Limb Lengthening and Reconstruction - International Center for Limb Lengthening - Rubin Institute for Advanced Orthopedics Baltimore

    Baltimore, Maryland

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.